Every 8-K that Establishment Labs Holdings Inc. (ESTA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ESTA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ESTA filings page.
Establishment Labs Holdings Inc. reported strong second-quarter 2026 growth, with revenue of $67.5 million, up 31.7% year over year and 12.8% sequentially. Motiva USA revenue rose to $24.7 million from $10.3 million a year earlier, and minimally invasive revenue reached $12.1 million. Gross margin improved to 70.6% from 68.8%, helped by higher-margin U.S. sales and its minimally invasive platform.
Loss from operations narrowed to $4.3 million from $14.1 million, and net loss improved to $11.7 million, or $0.39 per share. Adjusted EBITDA turned positive at $3.7 million versus a loss of $8.5 million in 2025. Cash and cash equivalents were $71.2 million as of June 30, 2026. Reflecting this performance, full-year 2026 revenue guidance was raised to $269–$271 million, up from $266.5–$268.5 million.
Establishment Labs Holdings Inc. has appointed Taylor Harris to its Board of Directors, effective immediately, to serve until the 2027 annual meeting of shareholders. He will also sit on the Audit Committee and the Nominating and Corporate Governance Committee.
Harris will receive the company’s standard non-employee director cash and equity compensation, including an updated initial equity grant of $170,000 for new directors and a $170,000 annual equity grant. The Board determined that all members of the Audit, Compensation, and Nominating and Corporate Governance Committees meet Nasdaq independence standards.
The accompanying press release highlights Harris’s 25+ years of experience in healthcare and medical technology, including leadership roles at Cutera, MyoKardia, Zeltiq Aesthetics, and Thoratec, and his involvement in major strategic transactions such as MyoKardia’s $13.1 billion acquisition by Bristol Myers Squibb.
Establishment Labs Holdings Inc. held its Annual Meeting of Shareholders on May 22, 2026. Shareholders elected six directors to serve until the 2027 annual meeting, including Filippo “Peter” Caldini, who received 20,009,113 votes for and 21,173 against, and Edward Schutter, who received 20,001,165 votes for and 29,105 against.
Shareholders also approved, on an advisory basis, the compensation of the company’s named executive officers with 19,999,556 votes for and 30,543 against, with 3,063,262 broker non-votes. In addition, they ratified the appointment of CBIZ, CPAs P.C. as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 22,686,230 votes for and 405,748 against.
Establishment Labs Holdings Inc. reported strong first-quarter 2026 results with revenue of $59.9 million, up 44.7% from the same period in 2025, driven by Motiva sales and minimally invasive products. Gross margin improved to 70.7%, and the company delivered its third consecutive quarter of positive adjusted EBITDA.
Net loss narrowed to $13.4 million from $20.7 million a year earlier, while cash used in the quarter fell to $7.5 million and cash on hand was $68.1 million as of March 31, 2026. Management raised full-year 2026 revenue guidance to a range of $266.5 million to $268.5 million and now expects the minimally invasive business to exceed $35 million, with positive adjusted EBITDA every quarter and free cash flow positivity in the second half of 2026.
Establishment Labs Holdings Inc. entered into an amended credit agreement with Oaktree-affiliated lenders providing term loans of up to $300,000,000. The facility includes a $265,000,000 Tranche E funded at closing and a Tranche F of up to $35,000,000 available upon mutual consent.
About $259,000,000 from Tranche E will repay all obligations under the prior credit agreement and related costs, with remaining proceeds for working capital and general corporate purposes. The term loans bear interest at 8.75% per annum with partial payment-in-kind options in the first year, mature on April 30, 2031, carry a 1% original issue discount and a 1% exit fee on repayments, and are subject to prepayment premiums in the first three years.
Establishment Labs Holdings Inc. reported strong growth for the fourth quarter and full year 2025 and issued upbeat 2026 guidance. Fourth quarter revenue was $64.6 million, up 45.2% from 2024, while full-year revenue reached $211.1 million, a 27.2% increase.
Gross margin improved to 70.5% in the quarter. The company cut its fourth quarter net loss from operations to $3.9 million from $18.7 million, and net loss narrowed to $2.6 million. Fourth quarter adjusted EBITDA turned positive at $5.5 million versus a $13.1 million loss a year earlier.
Cash was $75.6 million as of December 31, 2025, with a note payable to Oaktree of $247.5 million and shareholders’ equity of $23.5 million. For 2026, the company guides revenue to $264–266 million, implying growth of about 25–26%, and projects revenue growth of at least 25% in 2027.
Establishment Labs Holdings Inc. filed a Form 8-K to share that it presented at the J.P. Morgan Healthcare Conference on January 14, 2026. The company is furnishing, rather than filing, the investor presentation as Exhibit 99.1, meaning it is not subject to certain liability provisions that apply to filed information.
The report highlights that the materials may contain forward-looking statements and preliminary financial data prepared by management. The company notes that its independent registered public accounting firm, CBIZ, Inc., has not audited, reviewed, or provided any assurance on this preliminary financial information, so it should not be relied on as a substitute for full GAAP financial statements.
Establishment Labs Holdings Inc. reported that it has issued a press release with preliminary, unaudited financial information for the quarter and full year ended December 31, 2025. The press release, dated January 12, 2026, is furnished as Exhibit 99.1 to this report.
The company emphasizes that these consolidated preliminary estimates are forward-looking statements, may differ materially from actual results, and are not a substitute for full financial statements prepared under U.S. GAAP. Its independent registered public accounting firm, CBIZ, Inc., has not audited, reviewed, compiled, or performed any procedures on this preliminary information and does not provide any assurance on it.
Establishment Labs Holdings Inc. (ESTA) furnished an update on its business by announcing financial results for the three and nine months ended September 30, 2025. The company made these results available through a press release attached as Exhibit 99.1. The disclosure under Item 2.02 is furnished and not filed under the Exchange Act.
Establishment Labs Holdings Inc. entered into a fourth amendment to its credit agreement with Oaktree Fund Administration. The amendment makes the Tranche D term loans available as of the amendment’s effective date, removing the need to first achieve the revenue milestone originally required. It also raises the minimum liquidity the company and its guarantor subsidiaries must maintain from $25,000,000 to $30,000,000, effective September 28, 2025.
On the same day, the company fully drew the available Tranche D term loans, resulting in a new borrowing of $25,000,000 under the credit agreement. The amendment itself is filed as an exhibit to provide full details of the revised terms.